Firm
Attorneys at Gibson Dunn share why plaintiffs’ growing reliance on DMCA anti-circumvention claims in AI scraping cases exposes a critical vulnerability
US law firms highlight litigation profitability and client demand as driving forces behind a boom in lateral hires in the life sciences sector
Stobbs has successfully seen off a contempt of court application filed against the firm and two of its lawyers
After almost a quarter of a century, Marshall Gerstein has a new managing partner
Sponsored
Sponsored
-
Sponsored by Berken IPMaría Aurora García of Berken IP explains how Argentina’s evolving non-use cancellation system strengthens trademark integrity, streamlines registration, and promotes fairer market competition through efficient, partial, and administrative cancellation mechanisms
-
Sponsored by TOPPAN Digital IPManaging IP hears how TOPPAN Digital IP’s platform aims to streamline global patent management, combining artificial intelligence and human expertise to facilitate efficient filings, accurate translations, and smooth renewals in a single, secure environment
-
Sponsored by Licks AttorneysHow UK extraterritorial decisions are undermining Brazilian judicial sovereignty and violating TRIPSSenior patent attorneys at Licks Attorneys say recent UK court decisions on FRAND licensing conflict with Brazilian judicial sovereignty and the TRIPS framework governing the territorial independence of patents
-
Sponsored by Gün + PartnersSelin Sinem Erciyas of Gün + Partners explores the growing alignment between Turkish courts and the Unified Patent Court in applying a strictly technical-functional standard for patent infringement by equivalence
-
Sponsored by Liu, Shen & AssociatesWenjing Zhu of Liu, Shen & Associates explains how China’s administrative adjudication system is reshaping patent enforcement, offering faster, cost-effective, and technically expert resolutions for patentees, while preserving rights to pursue court remedies
-
Sponsored by Wanhuida Intellectual PropertyMinnan (Miranda) Xie of Wanhuida Intellectual Property analyses how China’s patent authorities and courts assess second medical use inventions, with key CNIPA decisions clarifying the treatment of dosage regimens and patient subgroups in novelty determinations